Nektar Therapeutics (NKTR) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Nektar Therapeutics.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.514 Hello and thank you for standing by. Welcome to the Nectar Therapeutics second quarter 00:00:05.514 -- 00:00:10.698 2026 financial results conference call. At this time, all participants 00:00:10.698 -- 00:00:15.481 are in a listen-only mode. After the speaker's presentation, there will be a question 00:00:15.481 -- 00:00:20.584 and answer session. Please be advised that today's conference is being recorded. 00:00:20.584 -- 00:00:25.407 I would now like to hand the conference over to Vivian Wu from Nectar Investor Relations 00:00:25.407 -- 00:00:28.556 to kick things off. Please go ahead. 00:00:28.556 -- 00:00:30.997 Thank you, Crystal, and good afternoon, everyone. 00:00:30.997 -- 00:00:33.357 Thank you for joining us today. 00:00:33.357 -- 00:00:37.539 On today's call, you will hear from Howard Robin, our President and Chief Executive Officer, 00:00:37.539 -- 00:00:42.360 Dr. Jonathan Zalevsky, our Chief Research and Development Officer, and Linda Rubinstein, 00:00:42.360 -- 00:00:44.781 our Chief Financial Officer. 00:00:44.781 -- 00:00:50.493 Dr. Mary Tagliaferri, our Chief Medical Officer, will also be available during the Q&A. 00:00:50.493 -- 00:00:54.235 Before we begin, I would like to remind you that we will be making forward-looking statements 00:00:54.235 -- 00:00:59.498 regarding our business, including statements related to therapeutic and commercial potential 00:00:59.498 -- 00:01:02.120 and development plans for Raspeg-Aldis-Lukin, 00:01:02.120 -- 00:01:07.083 the timing and expectations for clinical trials, clinical data presentations, and regulatory 00:01:07.083 -- 00:01:09.725 submissions. Regulatory 00:01:09.725 -- 00:01:11.266 interactions 00:01:11.266 -- 00:01:16.389 are expected cash runway and other statement...